title: Developing PAR1 antagonists: minding the endothelial gap.
abstract: Proteinase Activated Receptors (PARs) are G-protein coupled receptors (GPCRs) that were discovered in the early 1990's. They are unusual among GPCRs in being activated through proteolytic cleavage of the receptor N-terminus by serine proteinases such as thrombin. Over the last two decades major advances have been made in our understanding of how these receptors function and the roles they play in (patho)physiology. They have also emerged as drug targets for a number of conditions, most notably thrombosis. Recently two different drugs targeting PAR1 have entered clinical trials as anti-platelet agents. This review provides an overview of the proteinase activated receptor family and focuses on the role of PAR1 in regulating the endothelial barrier integrity and its implication on developing PAR antagonists for anti-platelet therapy.
authors: Department of Physiology and Pharmacology, Faculty of Medicine, University of Calgary, Calgary, Alberta T2N4N1, Canada. rramacha@ucalgary.ca
authors: Rithwik
authors: R
authors: Ramachandran
mesh_terms: D000818:Animals; D002318:Cardiovascular Diseases / Q000188:drug therapy; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D007783:Lactones / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011725:Pyridines / Q000627:therapeutic use; D044462:Receptors, Proteinase-Activated / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D013927:Thrombosis / Q000188:drug therapy
chemical_list: D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D044462:Receptors, Proteinase-Activated; C530299:vorapaxar